The DOI matches its Crossref record; 366 of the 371 references it cites were found in a registry or an index.
EASL Clinical Practice Guidelines: Drug-induced liver injury
Abstract
Idiosyncratic (unpredictable) drug-induced liver injury is one of the most challenging liver disorders faced by hepatologists, because of the myriad of drugs used in clinical practice, available herbs and dietary supplements with hepatotoxic potential, the ability of the condition to present with a variety of clinical and pathological phenotypes and the current absence of specific biomarkers. This makes the diagnosis of drug-induced liver injury an uncertain process, requiring a high degree of awareness of the condition and the careful exclusion of alternative aetiologies of liver disease. Idiosyncratic hepatotoxicity can be severe, leading to a particularly serious variety of acute liver failure for which no effective therapy has yet been developed. These Clinical Practice Guidelines summarize the available evidence on risk factors, diagnosis, management and risk minimization strategies for drug-induced liver jury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Drug-induced liver injury (DILI) is an uncommon adverse reaction to drugs, and other chemicals, including herbal and dietary supplements (HDS).”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“The vast majority of cases of DILI occur at therapeutic doses in a small proportion of individuals exposed to the drug, representing an idiosyncratic reaction, and therefore unpredictable based on the drug's mechanism of action and related to the uniqueness of the individual [1,2].”
From DILI Differences and Similarities between the US and Europe (2026) · cites this paper as [2]
In the citing paper
“In pediatric medicine, DILI is a rare clinical situation. However, it has high morbidity and mortality, and it is one of the most common causes of acute liver failure. Furthermore, its diagnosis is clinically challenging due to its low incidence and phenotypic variability [6,7,8].”
From Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM (2023) · cites this paper as [7]
In the citing paper
“The lack of a reliable diagnostic biomarker and evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“The lack of reliable diagnostic biomarkers and an evidence-based treatment paradigm has resulted in limited guidance on how to manage this aspect of DILI.2,25–27”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“However, drug rechallenge in DILI cases is potentially dangerous2,75 and is associated with risk of death or requirement for liver transplant.”
From Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report (2023) · cites this paper as [2]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“High TBil and ALP levels in the second month after an acute DILI episode and the biochemical nonresolution-6 model may help predict the risk of chronic injury and delayed recovery [26,72].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Although there are some ambiguities regarding how to score certain sections as well as suboptimal reliability, RUCAM can provide systematic and framed guidance for the assessment of patients with suspected DILI and is the most widely used tool [26,27,51,59].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
In the citing paper
“Its potential value in confirming or excluding hepatocellular injury in cases of elevated ALT levels from a suspected extrahepatic origin (e.g., muscle) has been evaluated [26,175].”
From Chinese guideline for the diagnosis and treatment of drug-induced liver injury: an update (2024) · cites this paper as [26]
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Ekor, M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00177 · Cited by 3,919
Alvarez, F., Berg, P. A., Bianchi, F. B., Bianchi, L., Burroughs, A. K., Cancado, E. L., Chapman, R. W., Cooksley, W. G. E., Czaja, A. J., Desmet, V. J., et al. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80297-9 · Cited by 2,903
The influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Ostapowicz, G., Fontana, R. J., Schiødt, F. V., Larson, A., Davern, T. J., Han, S. H. B., McCashland, T. M., Shakil, A. O., Hay, J. E., Hynan, L., et al. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-12-200212170-00007 · Cited by 2,227
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Acetaminophen‐induced acute liver failure
Larson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., REISCH, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,913
Simplified criteria for the diagnosis of autoimmune hepatitis
Hennes, E. M., Zeniya, M., Czaja, A. J., Parés, A., Dalekos, G. N., Krawitt, E. L., Bittencourt, P. L., Porta, G., Boberg, K. M., Hofer, H., et al. (2008) · Hepatology · doi:10.1002/hep.22322 · Cited by 1,901
Flagged first, then by citations
5 of the 371 references couldn’t be matched to a known paper.
Research works printed but not linked: 5
- Nicoletti, 2017, Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI) [Abstract], Hepatology, 66, A-25
- Lim, 2008, Association of HLA-B*1502 allele and carbamazepine-induced severe adverse cutaneous drug reaction among Asians, a review, Neurol Asia, 13, 15
- US Food & Drug Administration, 2017, Drugs
- Sanjuan-Jimenez, 2017, Prevalence of hepatitis E markers in Spanish patients with suspected drug-induced liver injury [abstract], Hepatology, 66, 423A
- Fernández-Castañer, 2008, An analysis of the causes, characteristics, and consequences of reexposure to a drug or compound responsible for a hepatotoxicity event, Rev Esp Enfermedades Dig, 100, 278
Cited by
Sorted by citations
Items 501–600 of 1,278
Drug-induced liver damage with cholestasis
Pereverzev, A. P., Ostroumova, O. D., & Кочетков, А. И. (2020) · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · doi:10.37489/2588-0519-2020-3-61-74 · Cited by 7
Liver injury during rivaroxaban treatment in a patient with AL amyloidosis
Marrinan, A., Shackleton, L., Kelly, C., Lavin, M., Glavey, S. V., Murphy, P., & Quinn, J. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03084-8 · Cited by 7
Khera, S., Ranjan, R., Ramachandran, S., & Beriwal, A. (2021) · BMJ Case Reports · doi:10.1136/bcr-2020-237512 · Cited by 7
Watanabe, M., Shibuya, A., Yokomori, H., & Koizumi, W. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6370-20 · Cited by 7
Brache, V., Vieira, C. S., Plagianos, M. G., Lansiaux, M., Merkatz, R. B., Sussman, H., Cochón, L., Tejada, A. S., Kumar, N., Loeven, D., et al. (2021) · Contraception · doi:10.1016/j.contraception.2021.06.010 · Cited by 7
Xiong, Y.-T., Wang, J.-F., Li, L., Bai, Z.-F., Liu, Y., Huang, A., Wang, K.-X., Fu, Y., Yang, W., Guo, C., et al. (2024) · iLIVER · doi:10.1016/j.iliver.2024.100095 · Cited by 6
Діденко, В. І., Кленіна, І. А., Tatarchuk, О. М., Hrabovska, O. I., & Петішко, О. П. (2021) · Regulatory Mechanisms in Biosystems · doi:10.15421/022201 · Cited by 6
Chronic Oral Amiodarone as a Cause of Acute Liver Failure
Martinez, E. C., Landazuri-Navas, S., Kaya, G., & Cinicola, J. (2023) · Journal of Medical Cases · doi:10.14740/jmc4044 · Cited by 6
Wei, X., Wang, L., Yang, B., Ma, Y., Yuan, W., & Ma, J. (2024) · Cancer Science · doi:10.1111/cas.16131 · Cited by 6
Drug-Induced Liver Injury Due to Doxycycline: A Case Report and Review of Literature
Nikolajevic, N., Nikolajevic, M., Pantić, I., Korica, B., Kotseva, M., Alempijevic, T. M., Jevtic, D., Madrid, C., & Dumic, I. (2024) · Cureus · doi:10.7759/cureus.59687 · Cited by 6
He, K., Wei, D., Liu, Q., Liu, X., Zhou, D., Chen, S., Zhu, D., & Xu, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-78183-y · Cited by 6
Ribociclib-induced autoimmune-like hepatitis: a case report
Kavgacı, G., Şahin, T. K., Sökmensüer, C., Balaban, H. Y., & Aksoy, S. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2433368 · Cited by 6
Drug‐Induced Liver Injury Caused by Metamizole: Identification of a Characteristic Injury Pattern
Weber, S., Erhardt, F., Allgeier, J., Saka, D., Donga, N., Neumann, J. H. L., Lange, C. M., & Gerbes, A. L. (2025) · Liver International · doi:10.1111/liv.70012 · Cited by 6
Tang, Y., Li, Y., Zhang, C.-R., Ye, Y., Qiu, T., Zhu, Z., & Zhao, J. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468357 · Cited by 6
Prevalence of Polypharmacy Among Patients with Chronic Liver Disease—A Narrative Literature Review
Szkultecka-Dębek, M., Bułaś, L., Skowron, A., & Drozd, M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14176263 · Cited by 6
Negi, C. K., Sakolish, C., Tsai, H.-H. D., Nitsche, K. S., Gang, H., Bajaj, P., Ferguson, S., Stanko, J. P., Hewitt, P. G., Kukla, D. A., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00554 · Cited by 6
Drug-induced liver injury in cancer patients
Ivashkin, V. T., Raikhelson, K. L., Palgova, L. K., Maevskaya, M. V., Gerasimova, O. A., Александровна, К. Э., Marchenko, N. V., & Baranovsky, A. Y. (2020) · Oncohematology · doi:10.17650/1818-8346-2020-15-3-80-94 · Cited by 6
Gonzalez-Jimenez, A., Suzuki, A., Chen, M., Ashby, K., Álvarez‐Álvarez, I., Andrade, R. J., & Lucena, M. I. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03013-3 · Cited by 6
Self-citationNagai, H., Shimada, T., Takahashi, Y., Nishikawa, M., Tozuka, H., Yamamoto, Y., Niwa, O., Takahara, Y., Fujita, A., Nagase, K., et al. (2022) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-022-00258-7 · Cited by 6
Autoimmunity associates with severity of illness in elderly patients with drug-induced liver injury
Xiong, Y., Wang, J., Niu, X.-X., Fu, Y., Wang, K., Wang, C., Li, Q., Wang, J., Zhao, J., & Ji, D. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1071709 · Cited by 6
Guagliano, G., Volpini, C., Sardelli, L., Vangosa, F. B., Visai, L., & Petrini, P. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202303349 · Cited by 6
Zhu, Z., Zhang, Y. L., Li, J., Han, Y., Wang, L., Zhang, Y., Geng, H., Zheng, Y., Wang, X. D., Sun, C., et al. (2024) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2024.116030 · Cited by 6
Clinical Features and Risk Factors for Drug-Induced Liver Injury: A Retrospective Study From China
Ma, X., Chen, Z., An, J., & Zhang, C. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.04.014 · Cited by 6
Ciricillo, J. A., Myer, A. S., Yeboah‐Korang, A., Osman, A., Rahim, F., Goldfarb, D. G., Sharma, Y., Louissaint, J., Sherman, K. E., & Fontana, R. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003147 · Cited by 6
Arvaniti, P., Olivas, I., Pascual‐Dapena, A., Riveiro‐Barciela, M., Esteban, P., Aguilar, A., Pérez-Medrano, I., Horta, D., Marcos, A. C., Salcedo, M., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70353 · Cited by 6
Self-citationOsuntokun, O. S., Olayiwola, G., Atere, T. G., Adedokun, K. I., & Oladokun, O. O. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.006 · Cited by 6
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_14 · Cited by 6
Adverse events associated with analgesics: A focus on paracetamol use
Popiołek, I., & Porębski, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820237-1.00028-4 · Cited by 6
Choi, W. J., Kim, G., Park, J., Jang, S., Jung, W. J., Shim, J., Park, Y., Choi, G. H., Kim, J., Jeong, S., et al. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e255 · Cited by 6
Tong, Y., Zhang, M., Zhang, M., Qi, Z., Wu, W., He, F., 何福亮, Zhang, X., Zhang, F., Li, T., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040603 · Cited by 6
Du, X., Liu, Z., Yu, H., Wang, Y., Zou, Z., Wei, H., Liang, J., Yang, D., Liu, Y., Zhang, J., et al. (2023) · Medicine · doi:10.1097/md.0000000000034698 · Cited by 6
Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option
Yang, H., Sung, P. S., Jung, E. S., Cho, S., Bae, S. H., & Kim, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01160 · Cited by 6
Safety considerations for the management of cholestatic itch
Trivella, J. P., & Levy, C. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1915984 · Cited by 6
Li, J., Li, C., Wang, X., Wang, Y., & Zhou, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2124 · Cited by 6
Novel Perspectives of Stem Cell Manufacturing and Therapies
Kitala, D., & Maurício, A. C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.82986 · Cited by 6
Hoo, C.-Z., Tan, K. C., Abdullah, S., Sim, B. L. H., Omar, H., & Tan, S.-S. (2022) · ACG Case Reports Journal · doi:10.14309/crj.0000000000000760 · Cited by 6
Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury
Hunyady, P., Herrmann, E. M., Bojunga, J., Friedrich-Rust, M., Pathil, A., Zeuzem, S., & Mihm, U. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002382 · Cited by 6
Gai, Z., Samodelov, S. L., Alecu, I., Hornemann, T., Grove, J. I., Aithal, G. P., Visentin, M., & Kullak-Ublick, G. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24033013 · Cited by 6
Self-citationIzawa, T., Travlos, G. S., Cortes, R. A., Clayton, N. P., Sills, R. C., & Pandiri, A. R. (2023) · Toxicologic Pathology · doi:10.1177/01926233231171101 · Cited by 6
Ларионова, В. Б., & Владимирович, С. А. (2020) · Oncohematology · doi:10.17650/1818-8346-2020-15-4-65-81 · Cited by 6
Cell-based approaches for the mechanistic understanding of drug-induced cholestatic liver injury
Timor-López, E., Tolosa, L., & Donato, M. T. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04016-0 · Cited by 5
‘Fulminant hepatic failure’ anesthesiologic considerations
Vetrugno, L., Alessandri, F., Toscano, A., Voza, A., & Deana, C. (2025) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000001530 · Cited by 5
Clinical guidelines. Drug-induced liver injury (DILI) in adults
Drapkina, O. M., Maev, I. V., Ахмедов, В. А., Вологжанина, Л. Г., Dolgushina, A. I., Игумнова, О. А., Козлова, И. В., Лазебник, Л. Б., Okovityi, S. V., Pirogova, I. Y., et al. (2024) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-232-12-5-48 · Cited by 5
Fu, J., Huang, Q., Sun, C., Li, S., Wang, Q., Sheng, Y., He, B., & You, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-10764-x · Cited by 5
Hu, K., Tian, H., Chen, S., Liu, Y., Wei, R., Chen, B., & Jia, Y. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13689 · Cited by 5
Wei, X., Cai, R., Wu, X., Su, Y., Lian, S., Nan, T.-T., Ye, X., & Wei, J. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-12005-y · Cited by 5
Zhou, G.-F., Qiu, C., Zhu, D., & Ao, J. (2025) · Scientific Reports · doi:10.1038/s41598-025-24282-3 · Cited by 5
Li, D., Wang, D., Huang, G., Liu, Q., Wang, Y., Zhang, R., Liu, S., & Du, Q. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102156 · Cited by 4
Bishnu, D., Santra, S., Purkait, S., & Santra, A. K. (2025) · International Journal of Hepatology · doi:10.1155/ijh/9980298 · Cited by 5
Usefulness of plasma bile acid profile as a prognostic biomarker for drug-induced liver injury
Monte, M. J., Tran, T. D., Grove, J. I., Li, D., Stephens, C. M., Lucena, M. I., Andrade, R. J., Weber, S., Gerbes, A. L., Bjornsson, E. S., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106229 · Cited by 5
Self-citationAmlodipine-Induced Liver Injury
Horman, J. Y. K., Patel, P. D., Schultz, M., & Kraschnewski, J. L. (2022) · Cureus · doi:10.7759/cureus.23441 · Cited by 5
Understanding liver function tests: part 1
Parsons, G. (2023) · Prescriber · doi:10.1002/psb.2079 · Cited by 5
Non-metabolic causes of steatotic liver disease
Nasr, P., Jönsson, C., Ekstedt, M., & Kechagias, S. (2023) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.20 · Cited by 5
Changing Perspectives: Unveiling the Risks of Ashwagandha-Induced Hepatotoxicity
Casiano-Manzano, S., Torres-Larrubia, M., Masa-Caballero, A., Jiménez-Colmenarez, Z., Martín-Noguerol, E., Fernández‐Bermejo, M., & Solís‐Muñoz, P. (2023) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2023.10080/2023 · Cited by 5
Mariottini, A., Barilaro, A., Lotti, A., Marra, F., & Massacesi, L. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1363493 · Cited by 5
Acute grade IV toxic hepatitis due to the e-cigarette
Roey, G. V., Goos, W., Claessens, C., Hoorens, A., Verlinden, W., & Schouten, J. N. L. (2024) · Acta gastro-enterologica belgica · doi:10.51821/87.1.11378 · Cited by 5
Attenuation of paracetamol-induced hepatotoxicity in Ajuga bracteosa extract treated mice
Ali, T., Jan, I., Bashir, R., Mir, S. A., Ali, S., & Bader, G. N. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33998 · Cited by 5
Rutaecarpine Aggravates Acetaminophen-Induced Acute Liver Injury by Inducing CYP1A2
Wan, M., Gao, H., Liu, X., & Zhang, Y.-B. (2024) · Toxics · doi:10.3390/toxics12070515 · Cited by 5
Raikhelson, K. L., Bueverov, A. O., Александровна, К. Э., Maevskaya, M. V., Борисович, Х. И., Shirokova, E. N., & Ivashkin, V. T. (2024) · Russian Journal of Gastroenterology Hepatology Coloproctology · doi:10.22416/1382-4376-2024-1167-3098-1 · Cited by 5
Roberts, J. A., Heffernan, A. J., Chai, M. G., Harris, P. N. A., Legg, A., Farkas, A., Laupland, K. B., Dhanani, J., Fourie, C., Murray, L., et al. (2024) · CMI Communications · doi:10.1016/j.cmicom.2024.105051 · Cited by 5
GNF-5837 attenuates acute liver injury by inhibiting oxidative stress
Zhou, X., Luo, X., Huang, Q., Ru, Y., Liu, D., Linghu, M., & Huang, Y. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10522-2 · Cited by 5
Tzoneva, D., Aleksiev, E., Michova, K., & Stanimirov, P. (2019) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2019.1649987 · Cited by 5
Menotrophin Induced Autoimmune Hepatitis
Alqrinawi, S. H., Akbar, N., AlFaddag, H., Akbar, S., Akbar, L., Butt, S. A., & Aljawad, M. (2019) · Case Reports in Gastrointestinal Medicine · doi:10.1155/2019/7343805 · Cited by 5
Noninvasive assessment of liver fibrosis in Crohn’s disease patients exposed to methotrexate
Llaó, J., Masnou, H., Romero, C., Bargalló, A., Gely, C., Mañosa, M., Gordillo, J., García-Planella, E., & Domènech, E. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001799 · Cited by 5
Hepatobiliary disease after bone marrow transplant
Dezan, M. G. F., Cavalcante, L. N., Cotrim, H. P., & Lyra, A. C. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2169671 · Cited by 5
Gao, Z., Wu, S., Yang, Y., Sun, M., Tian, X., & Jin, X. S. (2023) · Investigational New Drugs · doi:10.1007/s10637-023-01391-2 · Cited by 5
A Case Report: Idiopathic or Drug-Induced Autoimmune Hepatitis—Can We Draw a Line?
Božić, D., Tonkić, A., Vukojević, K., & Radman, M. (2023) · Clinics and Practice · doi:10.3390/clinpract13060125 · Cited by 5
Carrier, P., Debette‐Gratien, M., Jacques, J., Grau, M., & Loustaud-Ratti, V. (2020) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2020.06.020 · Cited by 5
Thurin, N. H., Lassalle, R., Schuemie, M. J., Pénichon, M., Gagne, J. J., Rassen, J. A., Bénichou, J., Weill, A., Blin, P., Moore, N. D., et al. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5161 · Cited by 5
Li, Y., & Zhou, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00008-6 · Cited by 5
Zhang, Z., Xu, L., Qin, N., Zhang, J., Xiang, Q., Liu, Q., Cheng, Y., Bai, Y., Liu, Q., Liu, Y., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13986 · Cited by 5
Clozapine-induced hepatotoxicity: A life threatening situation
Dias, C. L., Fonseca, L., Gadelha, A., & Noto, C. D. S. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.07.012 · Cited by 5
Marrone, G., Galati, F., Biolato, M., Oddy, C., Carolis, S. D., Zoli, A., & Grieco, A. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01878-3 · Cited by 5
Yamamoto, T., Ito, T., Mizuno, K., Shinya, Y., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., Kawashima, H., Matsui, T., et al. (2022) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13122 · Cited by 5
Wang, P., Guo, G., Jiang, S., Ding, D., Yang, J., Lü, Y., Han, Y., & Zhou, X. (2025) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2025.102635 · Cited by 4
Seo, H.-S., Kim, H.-G., Joo, H.-E., Kwon, J., & Cho, J.-H. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.120292 · Cited by 5
Hepatotropic therapy for drug-induced liver injury (expert meeting)
Okovityi, S. V., Raikhelson, K. L., Ахмедов, В. А., Вологжанина, Л. Г., Gladkov, O. A., Grechishnikova, V. R., Deeva, Т. A., Dolgushina, A. I., Жаркова, М. С., Козлова, И. В., et al. (2025) · Perm Medical Journal · doi:10.17816/pmj42358-74 · Cited by 4
López-Pascual, E., Moreno‐Torres, M., Moro, E., Rapisarda, A. S., Ortega-Vallbona, R., Serrano‐Candelas, E., Gozalbes, R., Jover, R., & Castell, J. V. (2025) · Archives of Toxicology · doi:10.1007/s00204-025-04178-x · Cited by 4
İlhan, N., Baş, S., Alkan, O., Doğan, A., Majidova, N., Tunç, M. A., Erdemoğlu, E., Öztosun, B., Ökten, I. N., & Gümüş, M. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06336-1 · Cited by 4
Yao, L., Zhou, J. J., Tan, Z., Li, C., He, T., Yin, Y., & Zhang, P. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-08085-y · Cited by 4
He, Y., Chen, X.-D., Wu, S., Zhou, C.-B., Wang, P., Tang, S., Sun, Y.-S., Zhang, C., Wang, B.-Z., Gao, C.-H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-24262-7 · Cited by 4
Hypertransaminasemia in non-cirrhotic critically-ill patients
Fiore, M., Cosenza, G., Coppolino, F., Pota, V., Sansone, P., Petrou, S., & Pace, M. C. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.109645 · Cited by 4
Hioki, T., Imoto, K., Goya, T., Azuma, Y., Horiuchi, A., Aoyagi, T., Takahashi, M., Oda, Y., Kato, M., Kohjima, M., et al. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04561-z · Cited by 4
Lian, X., Jiang, J., Yang, Y., Feng, Z., Zhang, X., Yuan, X., & Zhang, P. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.12.019 · Cited by 4
Human Leukocyte Antigen (HLA) Signatures and Idiosyncratic Drug-Induced Liver Injury
Onaciu, A., Grama, A., Agoston, S., Mititelu, A., Maris, B. R., Ştefănescu, H., & Pop, T. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010482 · Cited by 4
The incidence of chronic drug-induced liver injury: a systematic review and meta-analysis
Zhang, Y., Ren, Y., Song, X.-R., He, X.-J., & Wen, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1710414 · Cited by 4
Safety of in vivo gene therapy in children: mechanisms and management of liver injury
Jeyaraj, R., Brown, L. K., Jagadisan, B., Muntoni, F., Baruteau, J., Gupte, G. L., Breuer, J., Gissen, P., Oo, Y. H., & Dhawan, A. K. (2026) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(25)00380-3 · Cited by 4
Balsano, C., Alisi, A., Burra, P., Calvaruso, V., Cammà, C., Campagner, A., Donatelli, P., Germani, G., Gerussi, A., Giuffrè, M., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.03.005 · Cited by 4
Краснова, Н. М., Евдокимова, Н. Е., Egorova, A. A., Filippova, O. I., Алексеева, Е. А., Rudykh, Z. A., Chertovskikh, Y. V., Венгеровский, А. И., Кравченко, А. Ф., & Sychev, D. A. (2020) · Antibiot Khimioter = Antibiotics and Chemotherapy · doi:10.37489/0235-2990-2020-65-7-8-31-36 · Cited by 4
Drug‐induced liver injury in the era of biologics: The case of natalizumab
Taveira, F. T. L., Lopes, S., Faria, C., Mendes, S., & Figueiredo, P. (2021) · Advances in digestive medicine · doi:10.1002/aid2.13272 · Cited by 4
Wang, Y., Chen, X., Wang, Y., Zhong, H. P., Liu, L., & Ye, Y. (2023) · Medicine · doi:10.1097/md.0000000000036349 · Cited by 4
Petrović, S., Kovačević, M., Kovačević, S. V., & Miljković, B. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2322114 · Cited by 4
Feng, C., Ye, W., & Shan, Q.-W. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03701-w · Cited by 4
Urakawa, S., Shingai, T., Kato, J., Kidogami, S., Fukata, T., Nishida, H., Takemoto, H., Ohigashi, H., & Fukuzaki, T. (2024) · Surgery Today · doi:10.1007/s00595-024-02962-3 · Cited by 4
Jiang, J., Wang, Q., Wu, Q., Deng, B., Guo, C. X., Chen, J., Zeng, J., Guo, Y., & Ma, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1523713 · Cited by 4
He, M.-W., Cui, L., Chen, D., Zhao, Y., Luo, W.-Z., Jia, Y., Zhou, J., He, Q., Dai, Y., Zhang, W.-H., et al. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01827-24 · Cited by 4
Yamamoto, T., Ito, T., Suzuki, T., Mizuno, K., Yokoyama, S., Yamamoto, K., Imai, N., Ishizu, Y., Honda, T., & Kawashima, H. (2025) · Hepatology Research · doi:10.1111/hepr.14200 · Cited by 4
Nanozymes: new strategy for the management drug-induced acute liver injury
Kan, M., Wang, Y., Cheng, N., Huang, K., & He, X. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb00448a · Cited by 4
Zhang, H., Luo, J., Yi, Y., Yuan, L., Zhao, J., Zhao, Y., Zhou, H., Yao, J., & Jiang, H. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100134 · Cited by 4
Metadata
- Authors
- Andrade, R. J., Aithal, G. P., Björnsson, E. S., Kaplowitz, N., Kullak-Ublick, G. A., Larrey, D., & Karlsen, T. H.
- ORCID
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 70
- Issue
- 6
- Pages
- 1222-1261
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2924328881
- Semantic Scholar
- 6d774d1c570eef200451a1e8a8f5655c367a4eaf
- Cited by
- 1,276
- References
- 371
- Citations by year
- 2026: 243 · 2025: 211 · 2024: 175 · 2023: 159 · 2022: 158 · 2021: 184 · 2020: 117 · 2019: 27
- FWCI
- 78.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- European Cooperation in Science & Technology
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- drug-induced liver injury, idiosyncratic drug-induced liver injury, hepatotoxicity, acute liver failure, risk factors, diagnosis, risk minimization
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Histocompatibility Testing, Humans, Liver Neoplasms, Male, Middle Aged, Mitochondria, Risk Factors, Chemical and Drug Induced Liver Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
